A phase I first‐in‐human trial in patients with advanced HCC expressing FGF19 validated the safety and preliminary clinical activity of fisogatinib.[37, 41] In this study, IVIS and ultrasound imaging were used to quantify liver metastatic burden. Here, FGF19 is linked to hepatocellular carcinoma.